RUBY
Income statement / Annual
Last year (2022), Rubius Therapeutics, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2022, Rubius Therapeutics, Inc.'s net income was -$230.86 M.
See Rubius Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$96.41 M
|
$141.59 M
|
$116.11 M
|
$112.42 M
|
$51.77 M
|
$21.23 M
|
$8.40 M
|
| General & Administrative Expenses |
$30.84 M
|
$53.03 M
|
$50.34 M
|
$57.18 M
|
$39.89 M
|
$22.04 M
|
$2.45 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$30.84 M
|
$53.03 M
|
$50.34 M
|
$57.18 M
|
$39.89 M
|
$22.04 M
|
$2.45 M
|
| Other Expenses |
$0.00
|
$0.00
|
-$1.28 M
|
$0.00
|
$0.00
|
$0.00
|
-$16.00 K
|
| Operating Expenses |
$127.25 M
|
$194.62 M
|
$166.45 M
|
$169.60 M
|
$91.66 M
|
$43.26 M
|
$10.85 M
|
| Cost And Expenses |
$127.25 M
|
$194.62 M
|
$166.45 M
|
$169.60 M
|
$91.66 M
|
$43.26 M
|
$10.85 M
|
| Interest Income |
$819.00 K
|
$91.00 K
|
$1.76 M
|
$7.99 M
|
$5.12 M
|
$511.00 K
|
-$16.00 K
|
| Interest Expense |
$3.86 M
|
$6.43 M
|
$4.19 M
|
$2.59 M
|
$464.00 K
|
$309.00 K
|
$149.00 K
|
| Depreciation & Amortization |
$6.25 M
|
$7.72 M
|
$5.69 M
|
$3.00 M
|
$1.26 M
|
$447.00 K
|
$118.00 K
|
| EBITDA |
-$169.55 M |
-$182.39 M |
-$157.86 M |
-$157.87 M |
-$91.66 M |
-$42.31 M |
-$10.75 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
-$1.22 M
|
-$1.93 M
|
-$1.28 M
|
$6.14 M
|
$2.47 M
|
-$583.00 K
|
-$164.00 K
|
| Income Before Tax |
-$179.67 M
|
-$196.55 M
|
-$167.73 M
|
-$163.46 M
|
-$89.20 M
|
-$43.85 M
|
-$11.02 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$51.20 M
|
-$7.72 M
|
-$5.69 M
|
-$3.00 M
|
$0.00
|
$309.00 K
|
$0.00
|
| Net Income |
-$230.86 M
|
-$188.82 M
|
-$162.04 M
|
-$160.46 M
|
-$89.20 M
|
-$43.85 M
|
-$11.02 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-2.56 |
-2.15 |
-2.01 |
-2.04 |
-1.28 |
-5.13 |
-1.29 |
| EPS Diluted |
-2.56 |
-2.15 |
-2.01 |
-2.04 |
-1.28 |
-5.13 |
-1.29 |
| Weighted Average Shares Out |
$90.31 M
|
$87.95 M
|
$80.62 M
|
$78.69 M
|
$69.53 M
|
$8.54 M
|
$8.54 M
|
| Weighted Average Shares Out Diluted |
$90.31 M
|
$87.95 M
|
$80.62 M
|
$78.69 M
|
$69.53 M
|
$8.54 M
|
$8.54 M
|
| Link |
|
|
|
|
|
|
|
